INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.755
+0.065 (3.85%)
Jul 30, 2026, 3:00 PM EDT - Market open
INmune Bio Stock Forecast
Stock Price Forecast
According to 4 analysts polled by S&P Global, INmune Bio stock has a consensus rating of "Strong Buy" and an average price target of $7.00. The average 1-year stock price forecast is 298.86% higher than the current stock price, while the lowest is $4.00 (+127.92%) and the highest is $9.00 (+412.82%).
Price Target: $7.00 (+298.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for INmune Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +355.84% | Jul 10, 2026 |
| Alliance Global Partners | Alliance Global Partners | Buy Maintains $7 | Buy | Maintains | $7 | +298.86% | Apr 6, 2026 |
| Lucid Capital | Lucid Capital | Buy Upgrades $2 → $9 | Buy | Upgrades | $2 → $9 | +412.82% | Mar 11, 2026 |
Financial Forecast
Revenue This Year
n/a
from 50.00K
Decreased by -100.00%
Revenue Next Year
6.36M
EPS This Year
-0.60
from -1.19
EPS Next Year
-0.53
from -0.60
EPS and Forward PE are based on non-GAAP adjusted numbers.